ID   FM3.26
AC   CVCL_C579
SY   FM-3.26
DR   ECACC; 13012554
DR   ESTDAB; ESTDAB-009
DR   Wikidata; Q54835027
RX   PubMed=15592718;
CC   HLA typing: A*02:01,03:01; B*07:02,44:02; C*07:02,05:01; DPB1*04:01,13:01; DQB1*06:02,03:01:01; DRB1*04:01,15:01 (PubMed=15592718).
CC   Sequence variation: Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Right inguinal lymph node; UBERON=UBERON_0001542.
ST   Source(s): ECACC; ESTDAB
ST   Amelogenin: X
ST   CSF1PO: 11,13
ST   D13S317: 12
ST   D16S539: 12,13
ST   D3S1358: 15,17
ST   D5S818: 12
ST   D7S820: 10
ST   FGA: 23
ST   TH01: 6,9.3
ST   TPOX: 8,11
ST   vWA: 15,16
DI   NCIt; C3510; Cutaneous melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2046 ! FM3
SX   Female
AG   75Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 29-06-23; Version: 14
//
RX   PubMed=15592718; DOI=10.1007/s00262-004-0561-5;
RA   Rodriguez T., Mendez R., Roberts C.H., Ruiz-Cabello F., Dodi I.A.,
RA   Lopez Nevot M.A., Paco L., Maleno I., Marsh S.G.E., Pawelec G.,
RA   Garrido F.;
RT   "High frequency of homozygosity of the HLA region in melanoma cell
RT   lines reveals a pattern compatible with extensive loss of
RT   heterozygosity.";
RL   Cancer Immunol. Immunother. 54:141-148(2005).
//